Calixar Overview

  • Founded
  • 2011

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 19

Employees

  • Latest Deal Type
  • M&A

Calixar General Information

Description

Operator of a biotechnology company intended to preserve the original structure and function of membrane protein operations. The company engages in the production, extraction, stabilization, purification, and crystallization of functional membrane proteins and antigens, by isolating them in a native conformation without mutations or deletions, enabling biotechnology companies to develop conformational antibodies and formulate new vaccines efficiently.

Contact Information

Website
www.calixar.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Laboratory Services (Healthcare)
Parent Company
Eurofins Discovery
Primary Office
  • Bâtiment Laennec
  • 60A Avenue Rockefeller
  • 69008 Lyon
  • France
+33 04 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calixar Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 06-Apr-2023 00.000 Completed Generating Revenue
6. Secondary Transaction - Private 00.000 Completed Generating Revenue
5. Later Stage VC 13-Mar-2020 00.000 00.000 Completed Generating Revenue
4. Early Stage VC 24-Feb-2015 00.000 00.000 00.000 Completed Generating Revenue
3. Secondary Transaction - Private 17-Oct-2014 00.00 Completed Generating Revenue
2. Early Stage VC (Series A) 18-Jun-2012 $1.1M $1.1M 00.000 Completed Generating Revenue
1. Early Stage VC 01-Jan-2011 Completed Startup
To view Calixar’s complete valuation and funding history, request access »

Calixar Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A Preference 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.000
Class A Preference 33,400 $1.134983 $28.37 $28.37 1x $28.37 28.17%
To view Calixar’s complete cap table history, request access »

Calixar Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to preserve the original structure and function of membrane protein operati
Drug Discovery
Lyon, France
19 As of 2023
00.000
000000&0 00.000

000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000000000000
Houston, TX
00 As of 0000

000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repreh
0000000000000
San Diego, CA
000 As of 0000
0.00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Calixar Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cusabio Corporation Houston, TX 00
000000000 Corporate Backed or Acquired San Diego, CA 000 000000&0
00000 00000000000 Formerly PE-Backed Centennial, CO 000000&0
You’re viewing 3 of 3 competitors. Get the full list »

Calixar Patents

  • 17

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Calixar Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201601895-D0 Method for the synthesis of steroidic calixarene compounds, and their use for extraction, solubilization and/or stabilzation of native and functional membrane Inactive 03-Feb-2016 0000000000
CA-2959153-A1 Method for preparing a vaccine antigen, resulting vaccine antigen and uses Inactive 29-Aug-2014 000000000
FR-3025107-A1 Process for preparing a vaccinal antigen, vaccinal antigen obtained and uses Active 29-Aug-2014 000000000 0
US-10144917-B2 Method for preparing a vaccine antigen, resulting vaccine antigen and uses Inactive 29-Aug-2014 000000000
US-20170362578-A1 Method for preparing a vaccine antigen, resulting vaccine antigen and uses Active 29-Aug-2014 A61K39/12
To view Calixar’s complete patent history, request access »

Calixar Executive Team (6)

Name Title Board Seat Contact Info
Rodolphe Simonot Chief Executive Officer, President & Chairman
Pierre Falson Co-Founder & Scientific Advisor
Emmanuel Dejean Ph.D Business Advisor
You’re viewing 3 of 6 executive team members. Get the full list »

Calixar Board Members (1)

Name Representing Role Since
Rodolphe Simonot Calixar Chief Executive Officer, President & Chairman 000 0000
To view Calixar’s complete board members history, request access »

Calixar Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calixar Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ad-hoc Invest Angel Group Minority 000 0000 000000 0
Banque Populaire Corporation Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Crealys Venture Capital Minority 000 0000 000000 0
Grenoble Angels Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial